April 9, 2019 07:02 AM EDT
Deals

It’s a sell­er’s world in biotech M&A, and No­var­tis CEO Vas Narasimhan has his check book out and pen ready

John Carroll

Editor & Founder

The Al­con spin­off is of­fi­cial­ly done to­day, de­but­ing on the Swiss ex­change with a mar­ket cap of $25 bil­lion-plus, and No­var­tis CEO Vas Narasimhan is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times